tiprankstipranks
Trending News
More News >

Argenica Therapeutics Reports Promising Results for TBI Treatment

Story Highlights
Argenica Therapeutics Reports Promising Results for TBI Treatment

Confident Investing Starts Here:

Argenica Therapeutics Ltd ( (AU:AGN) ) has provided an announcement.

Argenica Therapeutics announced significant preclinical study results demonstrating that their therapeutic candidate, ARG-007, effectively reduces axonal injury and neuroinflammation in cases of moderate traumatic brain injury (TBI). The treatment showed promising outcomes by restoring biomarker levels to those of non-injured animals, suggesting its potential to mitigate both acute and chronic effects of TBI, potentially reshaping therapeutic approaches in the industry.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following brain injury.

YTD Price Performance: 11.11%

Average Trading Volume: 113,059

Technical Sentiment Consensus Rating: Sell

See more insights into AGN stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App